TCM
AST

Tradewinds Capital Management’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Tradewinds Capital Management’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-2
Closed – – 748
2016
Q3 		$0 Hold
2
– – ﹤0.01% 732
2016
Q2 		$0 Buy
+2
New +$7 ﹤0.01% 718
2016
Q1 		– Sell
-2
Closed – – 732
2015
Q4 		$0 Hold
2
– – ﹤0.01% 724
2015
Q3 		$0 Hold
2
– – ﹤0.01% 757
2015
Q2 		$0 Hold
2
– – ﹤0.01% 726
2015
Q1 		$0 Hold
2
– – ﹤0.01% 686
2014
Q4 		$0 Buy
+2
New +$8 ﹤0.01% 688

Other funds holding AST

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tradewinds Capital Management's AST Position: Q4 2016 in Review

Tradewinds Capital Management sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q4 2016, closing a stake of 2 shares.

Tradewinds Capital Management first reported a position in AST in Q4 2014 and held it in 7 quarters. The position peaked at $0 in Q3 2016. 66 funds tracked by Wall St. Rank hold AST as of Q4 2016.

  • Tradewinds Capital Management reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q4 2016 after selling out during the quarter.
  • Tradewinds Capital Management sold 2 Asterias Biotherapeutics Inc. Series A shares in Q4 2016.
  • Tradewinds Capital Management first reported a position in Asterias Biotherapeutics Inc. Series A in Q4 2014 and held it in 7 quarters.
  • Tradewinds Capital Management's Asterias Biotherapeutics Inc. Series A position peaked at $0 in Q3 2016.
  • 66 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q4 2016.

Based on Tradewinds Capital Management's 13F filing for Q4 2016, filed 3 Feb 2017.